Immuneering (IMRX) Cash & Current Investments: 2020-2024
Historic Cash & Current Investments for Immuneering (IMRX) over the last 4 years, with Sep 2024 value amounting to $50.7 million.
- Immuneering's Cash & Current Investments fell 47.91% to $50.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $267.3 million, marking a year-over-year decrease of 33.71%. This contributed to the annual value of $85.7 million for FY2023, which is 18.82% down from last year.
- As of Q3 2024, Immuneering's Cash & Current Investments stood at $50.7 million, which was down 15.19% from $59.7 million recorded in Q2 2024.
- Over the past 5 years, Immuneering's Cash & Current Investments peaked at $149.5 million during Q3 2021, and registered a low of $37.1 million during Q4 2020.
- In the last 3 years, Immuneering's Cash & Current Investments had a median value of $97.2 million in 2023 and averaged $95.8 million.
- As far as peak fluctuations go, Immuneering's Cash & Current Investments soared by 302.26% in 2021, and later slumped by 47.91% in 2024.
- Immuneering's Cash & Current Investments (Quarterly) stood at $37.1 million in 2020, then soared by 302.26% to $149.2 million in 2021, then decreased by 29.27% to $105.5 million in 2022, then decreased by 18.82% to $85.7 million in 2023, then crashed by 47.91% to $50.7 million in 2024.
- Its Cash & Current Investments was $50.7 million in Q3 2024, compared to $59.7 million in Q2 2024 and $71.3 million in Q1 2024.